Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined gut microbiota composition and plasma cytokine levels in thirty RT-PCR-confirmed COVID-19 patients at AIIMS Bhopal, India, compared with ten healthy controls. Patients spanned asymptomatic, mild, and severe disease groups.
How was it studied?
Stool DNA underwent 16S rRNA (V3-V4) sequencing to profile gut bacteria, while plasma samples were assayed for IFN-γ, TNF-α, and IL-21 using ELISA kits. Alpha and beta diversity were compared across severity groups using LEfSe.
What did they find?
The Firmicutes/Bacteroidetes ratio fell from 0.89 in healthy controls to 0.61, 0.51, and 0.42 in asymptomatic, mild, and severe patients respectively. This decline tracked depletion of fibre-utilizing genera including Faecalibacterium, Bacteroides plebeius, and Prevotella. Severe patients also had significantly higher IL-21 (17.54 ± 6.76 pg/mL) than mild patients (12.13 ± 3.71) and healthy controls (11.6 ± 2.07).
Why it matters
The findings link loss of fibre-fermenting gut commensals to both dysbiosis severity and heightened IL-21-driven inflammation in COVID-19. The authors suggest this points toward consortium-based microbial therapy rather than single-strain probiotics for restoring gut homeostasis.